Rapid Reviews COVID-19

Reviews of "Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary report"

Manish Sagar¹, Mike Samsonov²

¹Boston University School of Medicine, Medicine, USA,

²Associated Professor, Sechenov Moscow Medical Academy: Pervyj Moskovskij gosudarstvennyj medicinskij universitet imeni I M Secenova, Pharmacology, Russian Federation

Published on: Mar 01, 2021

License: [Creative Commons Attribution 4.0 International License \(CC-BY 4.0\)](https://creativecommons.org/licenses/by/4.0/)

To read the original manuscript, click the link above.

Summary of Reviews: *IL-6 receptor inhibitor therapy likely reduces morbidity and mortality in a select group of patients if used within 24 hours of worsening clinical status. Both reviewers considered the multi-center, placebo-controlled randomized control trial results to be strong.*

Reviewer 1 (Manish Sagar) | ☐☐☐☐☐

Reviewer 2 (Mike Samsonov) | ☐☐☐☐☐

RR:C19 Strength of [Evidence Scale Key](#)

☐ ☐☐☐ = Misleading

☐☐ ☐☐ = Not Informative

☐☐☐ ☐☐ = Potentially Informative

☐☐☐☐ = Reliable

☐☐☐☐☐ = Strong

To read the reviews, click the links below.